Alleviating Effects of AS1892802, a Rho Kinase Inhibitor, on Osteoarthritic Disorders in Rodents

被引:20
作者
Takeshita, Nobuaki [1 ]
Yoshimi, Eiji [1 ]
Hatori, Chie [1 ]
Kumakura, Fumiyo [1 ]
Seki, Nobuo [1 ]
Shimizu, Yasuaki [1 ]
机构
[1] Astellas Pharma Inc, Pharmacol Res Labs, Tsukuba, Ibaraki 3058585, Japan
关键词
osteoarthritis; Rho kinase inhibitor; cartilage; pain; inflammation; DEGENERATIVE JOINT DISEASE; CHONDROGENIC DIFFERENTIATION; NEUROPATHIC PAIN; PROTEIN-KINASE; MOUSE KNEE; RAT MODELS; ACTIVATION; INTERLEUKIN-1-BETA; EXPRESSION; MORPHOLOGY;
D O I
10.1254/jphs.10319FP
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effects of AS 1892802, a selective Rho-associated coiled coil kinase (ROCK) inhibitor, on knee cartilage damage and pain behavior were examined in a rat model of osteoarthritis (OA). Monoiodoacetate (MIA) was intraarticularly injected into the right knee joints of rats. ROCK I and II mRNA levels increased in knee joints of MIA-injected rats. Our newly synthesized ROCK inhibitor, AS1892802, was injected into the ipsilateral knee or administered p.o. for 3 weeks. The compound dose-dependently and significantly inhibited of cartilage damage in the tibial plateau in a dose-dependent manner and decreased the weight distribution deficit associated with MIA injection. In addition, the compound also inhibited bradykinin induced pain responses in normal rats. In vitro, the compound could induce chondrocyte differentiation in a chondrogenic cell line and significantly inhibited IL-1 beta- or bradykinin-induced prostaglandin E-2 production in a synovial cell line. AS1892802 prevents cartilage damage induced by MIA and has analgesic effects in rat pain models, suggesting that AS1892802 may be clinically useful for the treatment of OA.
引用
收藏
页码:481 / 489
页数:9
相关论文
共 46 条
  • [41] Simultaneous Effects of a Selective EP2 Agonist, Omidenepag, and a Rho-Associated Coiled-Coil Containing Protein Kinase Inhibitor, Ripasudil, on Human Orbital Fibroblasts
    Hikage, Fumihito
    Watanabe, Megumi
    Sato, Tatsuya
    Umetsu, Araya
    Tsugeno, Yuri
    Furuhashi, Masato
    Ohguro, Hiroshi
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2023, 39 (07) : 439 - 448
  • [42] Short-Term Effects of Y-27632, a Rho-Associated Protein Kinase Inhibitor, on Chromatin Supraorganization and DNA Amount in Epithelial Cells of the Rat Cornea and Limbus
    Aldrovani, Marcela
    Barros Sobrinho, Alexandre A. F.
    Mairos, Fernanda Santos
    Laus, Jose Luiz
    CORNEA, 2017, 36 (07) : 845 - 853
  • [43] Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study
    Tanihara, Hidenobu
    Inoue, Toshihiro
    Yamamoto, Tetsuya
    Kuwayama, Yasuaki
    Abe, Haruki
    Suganami, Hideki
    Araie, Makoto
    ACTA OPHTHALMOLOGICA, 2015, 93 (04) : E254 - E260
  • [44] Fasudil, a Rho-kinase inhibitor, prevents intima-media thickening in a partially ligated carotid artery mouse model: Effects of fasudil in flow-induced vascular remodeling
    Zhang, Xiangyu
    Zhang, Tao
    Gao, Fu
    Li, Qingle
    Shen, Chenyang
    Li, Yankui
    Li, Wei
    Zhang, Xiaoming
    MOLECULAR MEDICINE REPORTS, 2015, 12 (05) : 7317 - 7325
  • [45] Differential effects of Rho-kinase inhibitor and angiotensin II type-1 receptor antagonist on the vascular function in hypertensive rats induced by chronic L-NAME treatment
    Chen, Bainian
    Shi, Lili
    Yu, Xiaoyan
    Sun, Jialin
    Zhang, Hengai
    Wang, Shoubao
    Fang, Lianhua
    Du, Guanhua
    ACTA PHARMACEUTICA SINICA B, 2012, 2 (05) : 450 - 458
  • [46] Synergistic effects of Rho kinase inhibitor Y-27632 and Noggin overexpression on the proliferation and neuron-like cell differentiation of stem cells derived from human exfoliated deciduous teeth
    Yang, Si
    Xin, Cuijuan
    Zhang, Bo
    Zhang, Hongbo
    Hao, Yunpeng
    IUBMB LIFE, 2020, 72 (04) : 665 - 676